News
Shares of Sarepta Therapeutics ( NASDAQ: SRPT) rose on Wednesday after the market as it reported second quarter revenue and ...
After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...
Zacks Investment Research on MSN1h
Sarepta Therapeutics (SRPT) Reports Q2 Earnings: What Key Metrics Have to Say
Sarepta Therapeutics (SRPT) reported $611.09 million in revenue for the quarter ended June 2025, representing a year-over-year increase of 68.4%. EPS of $2.02 for the same period compares to $0.07 a ...
Sarepta Therapeutics (SRPT) stock in focus as report says company hired a Trump-linked lobbying firm after deaths linked to ...
Analysts expect Sarepta Therapeutics to report an earnings per share (EPS) of $1.01. The announcement from Sarepta ...
We recently compiled a list of 11 Best Future Stocks to Buy Now. Arrowhead Pharmaceuticals, Inc. stands seventh on our list.
Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a ...
Stock of Sarepta Therapeutics Inc. (NASDAQ: SRPT) surged 38.89% in Tuesday pre-market following the U.S. Food and Drug ...
Report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA ...
The European Medicines Agency’s drug advisory committee (CHMP) rejected Elevidys for children aged 3 to 7 years who are able ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback